Lebwohl MG, Sugarman JL, Gold LS, Lin T, Martin G. Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials. J of Skin [Internet]. 2019Nov.9 [cited 2024Jul.22];3:S29. Available from: https://jofskin.org/index.php/skin/article/view/756